AiCure stands out as a leader in the application of AI and advanced data analytics in clinical trials, offering remote patient engagement and real-time monitoring of patient dosing, which enhances the predictability of study timelines and reduces costs. The company's competitive edge is further solidified by its impressive portfolio of over 65 issued patents, global presence in over 30 countries, and recognition through prestigious awards such as the Scrip Award, AI 100, and Digital Health 150. AiCure's culture of transparency and collaboration is evident in its OpenDBM platform, which allows the scientific community to access and apply AiCure’s digital biomarker algorithms to their own data sets, fostering research collaboration and enhancing understanding of disease progression.